Vanguard Group Inc. Boosts Stock Position in NeoGenomics, Inc. (NASDAQ:NEO)

Vanguard Group Inc. lifted its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 1.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,239,887 shares of the medical research company's stock after buying an additional 195,793 shares during the quarter. Vanguard Group Inc. owned approximately 11.09% of NeoGenomics worth $234,673,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. SBI Securities Co. Ltd. purchased a new stake in shares of NeoGenomics in the fourth quarter worth $26,000. Versant Capital Management Inc boosted its stake in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after purchasing an additional 1,142 shares in the last quarter. Quarry LP purchased a new stake in NeoGenomics during the 3rd quarter valued at about $40,000. Smartleaf Asset Management LLC increased its stake in NeoGenomics by 203.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after purchasing an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after buying an additional 1,103 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NEO shares. Piper Sandler lowered their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Bank of America dropped their price objective on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. The Goldman Sachs Group decreased their target price on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Finally, Needham & Company LLC decreased their price objective on shares of NeoGenomics from $19.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.60.

Remove Ads

NeoGenomics Stock Performance

Shares of NASDAQ NEO traded down $0.22 during trading on Thursday, hitting $8.90. The company had a trading volume of 2,468,281 shares, compared to its average volume of 930,316. NeoGenomics, Inc. has a 12 month low of $8.05 and a 12 month high of $19.12. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The firm has a market capitalization of $1.14 billion, a P/E ratio of -14.35 and a beta of 1.41. The stock has a 50 day simple moving average of $10.68 and a 200 day simple moving average of $13.81.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. As a group, analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.